Preclinical validation showed that X4.5dianilinophthalimide significantly suppressed NUP153 activity in adrenal cortical carcinoma (ACC), pheochromocytoma and paraganglioma (PCPG), and READ, while Imatinib exhibited similar inhibitory effects in STAD (Figure 8C). This evidence concerns the gene NUP153 and adrenal cortex carcinoma.